Immuneering Announces Pricing of Upsized Initial Public Offering
29 juil. 2021 22h48 HE
|
Immuneering Corporation
CAMBRIDGE, Mass., July 29, 2021 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates...
Immuneering Appoints Michael Bookman as General Counsel and Secretary
20 juil. 2021 06h47 HE
|
Immuneering Corporation
CAMBRIDGE, Mass., July 20, 2021 (GLOBE NEWSWIRE) -- Immuneering Corporation (“Immuneering”), a private biopharmaceutical company advancing a robust pipeline of oncology and neuroscience drug...
Immuneering Expands Board of Directors with Appointment of Ann E. Berman
14 juil. 2021 06h47 HE
|
Immuneering Corporation
CAMBRIDGE, Mass., July 14, 2021 (GLOBE NEWSWIRE) -- Immuneering Corporation (“Immuneering”), a private biopharmaceutical company advancing a robust pipeline of oncology and neuroscience drug...
Immuneering Expands Board of Directors with Addition of Senior Biotechnology Executive Laurie Keating
27 avr. 2021 10h17 HE
|
Immuneering Corporation
CAMBRIDGE, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- Immuneering Corporation (“Immuneering”) today announced the addition of Laurie Keating to its board of directors. Ms. Keating brings more than 25...
Immuneering Appoints Biren Amin, M.B.A., as Chief Financial Officer
06 avr. 2021 10h17 HE
|
Immuneering Corporation
CAMBRIDGE, Mass., April 06, 2021 (GLOBE NEWSWIRE) -- Immuneering Corporation today announced the appointment of Biren Amin, M.B.A., as Chief Financial Officer. Mr. Amin comes to Immuneering from...
Immuneering Expands Leadership Team with Appointment of Carolina Garcia Rizo, Ph.D., MBA, as Chief Business Officer
25 mars 2021 10h17 HE
|
Immuneering Corporation
CAMBRIDGE, Mass., March 25, 2021 (GLOBE NEWSWIRE) -- Immuneering Corporation today announced Carolina Garcia Rizo, Ph.D., MBA, has joined the company as chief business officer. Dr. Rizo brings to...
Immuneering Completes Oversubscribed $62 Million Series B Financing
05 janv. 2021 08h00 HE
|
Immuneering Corporation
CAMBRIDGE, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Immuneering Corporation today announced the completion of an oversubscribed $62 million Series B financing led by Cormorant Asset Management, with...
Immuneering to Present at Oppenheimer's Private Life Sciences Company Call Series
11 août 2020 10h17 HE
|
Immuneering Corporation
CAMBRIDGE, Mass., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Immuneering Corporation today announced the company’s participation in Oppenheimer’s Private Life Sciences Company Call Series taking place...
Immuneering to Present at the Inaugural LifeSci Partners Private Company Virtual Summer Symposium
28 juil. 2020 10h17 HE
|
Immuneering Corporation
CAMBRIDGE, Mass., July 28, 2020 (GLOBE NEWSWIRE) -- Immuneering Corporation today announced the company’s participation in the LifeSci Partners Private Company Virtual Summer Symposium, taking place...
Immuneering Enters Collaboration with Astex Pharmaceuticals to Identify Novel Therapeutic Targets in Central Nervous System Disorder Using Disease Cancelling Technology
25 juin 2020 10h17 HE
|
Immuneering Corporation
CAMBRIDGE, Mass., June 25, 2020 (GLOBE NEWSWIRE) -- Immuneering Corporation today announced a collaboration between its neuroscience division, known as Alleo Labs, and Astex Pharmaceuticals (UK), a...